Progression-free survival of 23 months with second-line trastuzumab deruxtecan in HER2-positive gastroesophageal junction adenocarcinoma: a case report
Authors: Dong, Yuanmei; Zhang, Li; Zhao, Lan; Zhu, Yanyun
Source journal: Frontiers in pharmacology (2026-01-01)
DOI: 10.3389/fphar.2026.1913044
Abstract
INTRODUCTION: Trastuzumab deruxtecan (T-DXd) has been approved for the second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer, revolutionizing the treatment landscape for this clinical scenario. CASE PRESENTATION: Given the lack of real-world evidence, here we reported a patient with HER2-positive, metastatic gastroesophageal junction adenocarcinoma treated with T-DXd in the second-line setting. The patient, a 63-year-old male, previously received first-line treatment with trastuzumab plus oxaliplatin, capecitabine and sintilimab but disease progression occurred at 4.5 months. He subsequently received T-DXd-based therapy for a total of 22 treatment cycles and achieved a progression-free survival (PFS) of 23 months, with improved performance status and no T-DXd treatment dose reduction during treatment. CONCLUSION: This case firstly supplements the real-world data of T-DXd for patients with HER2-positive advanced gastric cancer in the second-line setting. These data indicate the PFS benefit with second-line T-DXd-based treatment even after rapid progression on trastuzumab-based therapy and the safety of full-dose T-DXd during long-course treatment.
Related topics
Related open access articles
- Effects of ATRA on proliferation, migration and cell cycle of gastric cancer MGC-803 cells
- Caveolin-1 inhibits proliferation and migration of gastric cancer cell via inactivating BMI-1
- Expression of Oct4 and RhoA in gastric cancer and their correlation with clinicopathological characteristics
- Effects of Black Vinegar and Niacinamide on LPS-Induced Inflammation on Human Keratinocytes
- Protective effect of kudzu root vinegar and adenosine against UVB-induced oxidative stress in human keratinocytes
- MicroRNA-20a-3p and microRNA-20a-5p exhibit anti-proliferative activities in a melanoma in vitro model
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.